At present, there is limited evidence for the role of enteral nutrition as a primary therapy in cancer patients. Cachexia commonly occurs in patients with advanced cancer. A consensus view from a large number of studies suggests that cachexia cannot be fully reversed by vigorous enteral nutritional support. A review is included of the available data on the effects ofenteral nutritional support on the common indices of nutritional state and on the final outcome of patients receiving enteral nutrition in conjunction with radiotherapy or chemotherapy, or both. The 'nutritional' effects are probably limited because the duration of the nutritional support in most studies consists of a few weeks while malnutrition in the cancer patients often occurs over many months.
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(Gut 1994; supplement 1: S65-S68) There is some evidence that enteral nutrition is probably not successful as a primary therapy in many patients with the cancer cachexia syndrome. The suggestion derives from metabolic balance studies done in humans.
The techniques used to undertake such studies are based on the assumption that certain elements are found in comparatively fixed proportions in normal lean body mass. If an organism retains these elements in these ratios, it may be right to assume that normal lean body mass is being formed; conversely significant deviation from these ratios, as occurs in cancer patients, means that normal lean body mass is not being repleted and that the elements retained are being used for other purposes.
In certain circumstances, however, enteral nutrition may be useful in cancer patients whose weight loss is exacerbated by such complications as fistulas, short bowel obstruction, and vomiting or malabsorption induced by the tumour itself or the treatment. There may also be patients who, at different times in the course of their disease, may gain transient benefit from nutritional support.
In this paper we will discuss the effects of enteral nutrition on the nutritional state of cancer patients and its role in conjunction with other treatments. Finally, the possible effect of enteral nutrition on tumour growth in humans is discussed.
Enteral nutrition and nutritional state Although the first controversial papers on nasogastric feeding with milk based formulas date back to the 1950s,1-3 substantial experience has been gained in the past decade (Table I) (Table II) .
With regard to immune function, increases in some fraction of the complement cascade have been described and in a number of studies increases in lymphocyte counts have been reported (Table III) . Twenty patients were randomised to receive an enteral diet by needle catheter jejunostomy or the standard postoperative 5% dextrose solution. Improved nitrogen balance was noted in the patients receiving enteral nutrition. The length of hospital stay, however, was similar between the groups; the incidence of infectious complications was not reported.
In a controlled, non-randomised study performed in our Institute7 in patients with squamous cell carcinoma of the oesophagus receiving chemotherapy and radiation therapy, we showed that an enteral nutrition regimen of 37 kcal/kg/day and 2-1 g protein/kg/day for one month could maintain the nutritional state of patients in the treatment group, which in turn deteriorated in the control group. No other benefits in terms of either compliance or response to the oncological treatment, or survival was described (Table V) There were no differences in response or survival rates; tube fed patients had significantly longer radiation toxicity, mean (SEM) (3 3 (1 9) weeks v 1-8 (08)).
Enteral nutrition and tumour growth
Scientific data on the effect of enteral nutrition on the tumoral growth in humans are scanty, anecdotal,28 29 and the results of two studies on patients with head-neck cancer is conflicting (Table VI) .
We speculated that, if it is true that there is a relation between nutrient availability and tumour growth, then we should see the highest cancer cell proliferation rate in well nourished patients; consequently we tested this hypothesis statistically by evaluating the correlation between some nutritional variables (albumin, cholinesterase, number of lymphocytes, and body weight loss) with the labelling index in 136 adult patients with non-Hodgkin's lymphoma. The results obtained (Table VII) in this large population of patients do not support the view that a good nutritional state could result in a faster tumour growth as the opposite statistical association was found.
Our present view therefore is that any We conclude that enteral nutrition is usually feasible in malnourished anorexic cancer patients even when they are receiving radiotherapy or chemotherapy. The nutritional efficacy of enteral nutrition is, however, limited.
Evidence from controlled clinical trials suggest that the main benefits are the maintenance of, or prevention of, further deterioration in nutritional state rather than restoration of normal nutritional state. At present there is no evidence that the effectiveness of radiotherapy or chemotherapy is enhanced by concomitant enteral nutrition. Nevertheless, it is indicated in patients receiving such treatment to preserve nutritional state. In our view, it would be unethical to randomise such patients in clinical trials to receive no nutritional support. As yet there is no proof that nutritional support enhances the kinetics of tumour kinetics. Clearly further work is required to characterise the cause of cancer cachexia. If it proves possible to counteract these then more benefits of concomitant nutritional support will probably, and hopefully, be identified.
